Degradation of IKAROS prevents epigenetic progression of T cell exhaustion in a novel antigen-specific assay

Tristan Tay,Gayathri Bommakanti,Elizabeth Jaensch,Aparna Gorthi,Iswarya Karapa Reddy,Yan Hu,Ruochi Zhang,Aatman Doshi,Sin Lih Tan,Verena Brucklacher-Waldert,Laura Prickett,James Kurasawa,Michael Glen Overstreet,Steven Criscione,Jason Daniel Buenrostro,Deanna A. Mele

DOI: https://doi.org/10.1101/2024.02.22.581548

2024-02-24

Abstract:In cancer, chronic antigen stimulation drives effector T cells to exhaustion, limiting the efficacy of T cell therapies. Recent studies have demonstrated that epigenetic rewiring governs the transition of T cells from effector to exhausted states and makes a subset of exhausted T cells non-responsive to PD1 checkpoint blockade. Here, we describe an antigen-specific assay for T cell exhaustion that generates T cells that are phenotypically and transcriptionally similar to those found in human tumors. We performed a screen of human epigenetic regulators, identifying and validating IKAROS as a driver of T cell exhaustion. We found that the IKAROS degrader iberdomide prevents exhaustion by blocking chromatin remodeling at T cell effector enhancers and preserving binding of AP-1, NF-κB, and NFAT. Thus, our study uncovered a role for IKAROS as a driver of T cell exhaustion through epigenetic modulation, providing a rationale for the potential use of iberdomide in solid tumors to prevent T cell exhaustion.

Genomics